Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00864760 · ClinicalTrials.gov registry record · Phase 1
A Relative Bioavailability Study of Gabapentin 800 mg Tablets Under Fasting Conditions
A Phase 1 study, sponsored by Actavis.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00864760: Completed Phase 1 study, sponsored by Actavis.
NCT00864760 is a Phase 1 study that has completed, run by Actavis. The registered enrollment target is 30 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00864760, a Phase 1 study, has completed, sponsored by Actavis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the relative bioavailability of 800 mg Gabapentin Tablets by Purepac Pharmaceutical Co. with that of 400 mg (2 x 400 mg) NEURONTIN® by Parke-Davis under fasting conditions.
Interventions
- DRUG Gabapentin 800 mg tablets, single dose (1 tablet)
- DRUG NEURONTIN® 400 mg capsules, single dose (2 capsules)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 1999-06 |
| Est. Completion | 1999-06 |
| Phase | Phase 1 |
What the finished NCT00864760 record still lists
NCT00864760 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower).
The record links to 0 conditions, and to 2 interventions - of which Gabapentin 800 mg tablets, single dose (1 tablet) is the first listed.
NCT00864760 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00864760 about?
NCT00864760 is a clinical study titled "A Relative Bioavailability Study of Gabapentin 800 mg Tablets Under Fasting Conditions". The purpose of this study is to compare the relative bioavailability of 800 mg Gabapentin Tablets by Purepac Pharmaceutical Co. with that of 400 mg (2 x 400 mg) NEURONTIN® by Parke-Davis under fasting conditions.
What is the current status of trial NCT00864760?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 1999-06. Estimated completion is 1999-06.
What interventions are being tested in trial NCT00864760?
The interventions under investigation include: Gabapentin 800 mg tablets, single dose (1 tablet) (DRUG), NEURONTIN® 400 mg capsules, single dose (2 capsules) (DRUG).
Who is sponsoring clinical trial NCT00864760?
This trial is sponsored by Actavis, which has 79 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00864760's enrollment target sits among peer trials
30 1332nd of 2000 higher than 561 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia